For the better part of the past year, the narrative surrounding Intercept Pharmaceuticals (ICPT) has been the potential of its Ocaliva as a treatment for NASH… nonalcoholic steatohepatitis. And, that’s been the case for good reason. The company’s clinical trials of the drug as a therapy for NASH are not only in their latter stages, an update of the so-called Regenerate study is due before the end of the current quarter. With a piece of a $20 billion market at stake, investors are understandably anxious.
They’re also increasingly bullish on the matter.
After